Clinical Trial Results:
Denosumab and male infertility: a prospective intervention study
Summary
|
|
EudraCT number |
2015-000655-24 |
Trial protocol |
DK |
Global end of trial date |
10 May 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jun 2021
|
First version publication date |
25 Jun 2021
|
Other versions |
|
Summary report(s) |
RANKL regulates male reproductive function |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CBG-study2
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Dept. of growth and reproduction
|
||
Sponsor organisation address |
Blegdamsvej 9, copenhagen, Denmark, 2100
|
||
Public contact |
martin blomberg jensen, rigshospitalet, 45 35451865, blombergjensen@gmail.com
|
||
Scientific contact |
martin blomberg jensen, rigshospitalet, 45 35451865, blombergjensen@gmail.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Jan 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Apr 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
10 May 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
to investigate whether short term Denosumab treatment can imporve sperm count and male fertility
|
||
Protection of trial subjects |
regular blood sampling and clinical controls at department
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Mar 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
12
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
through out patient clinic | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
male infertility | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
no blinding. Only one arm
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Denosumab | ||||||||||||
Arm description |
denosumab | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
denosumab
|
||||||||||||
Investigational medicinal product code |
9001231
|
||||||||||||
Other name |
prolia
|
||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
60 mg s.c. once
|
||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Denosumab
|
||
Reporting group description |
denosumab |
|
|||||||||
End point title |
change in semen concentration [1] | ||||||||
End point description |
|||||||||
End point type |
Primary
|
||||||||
End point timeframe |
180 days
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: There is only ONE ARM in this study. We performed ANOVA with Dunnett's post hoc test, comparing changes in semen quality to baseline values. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
180 days
|
||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
ICD10 | ||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
overall trial
|
||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: We did not experince non-serious adverse events |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/33893301 |